key: cord-0011938-8aio9o5y
authors: Kuo, Chia-Ling; Pilling, Luke C; Atkins, Janice L; Masoli, Jane A H; Delgado, João; Kuchel, George A; Melzer, David
title: ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank
date: 2020-07-04
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glaa169
sha: bfb5f89a8e743780908740724074ce5688e8515d
doc_id: 11938
cord_uid: 8aio9o5y

nan

M a n u s c r i p t 2 We previously reported that the ApoE e4e4 genotype was associated with COVID-19 test positivity (OR=2.31, 95% CI: 1.65 to 3.24, p=1.1910 -6 ) [1] in the UK Biobank (UKB) cohort, during the epidemic peak in England, from March 16 to April 26, 2020 [2] . With more COVID-19 test results (March 16 to May 31, 2020) and mortality data (to March 31, 2020, with incomplete data for April, 2020) linked to UKB, we re-evaluated the ApoE e4 allele association with COVID-19 test positivity, and with all-cause mortality following test-confirmed COVID-19.

We restricted analyses to European-ancestry participants [3] (n=451,367, 90% of sample) attending baseline assessment centers in England (n=398,073) and excluded participants who died before the pandemic (set at February 1, 2020, n=22,384). Single nucleotide polymorphism data for rs429358 and rs7412 were used to determine ApoE genotypes. Our outcomes of interest were: a) COVID-19 test positive versus the rest of the sample meeting inclusion criteria (i.e., including untested samples and tested negative), and b) tested positive and died versus the rest of the sample as above, but with additional exclusion of test positive participants who survived. Some of the excluded samples could have died but cannot be identified due to incomplete mortality data for April, 2020. Logistic regression models compared ApoE e4e4 participants (or e3e4s) to e3e3s with adjustment for sex; age on April 26 th or age at death; baseline UKB assessment center in England (accounting for geographical differences in viral exposures); genotyping array type; and the top five genetic principal components (accounting for possible population admixture). (Table 1 ). In logistic models, ApoE e4e4 genotype was associated with increased risks of test positivity (OR=2.24, 95% CI:

A c c e p t e d M a n u s c r i p t 3 1.72 to 2.93, p=3.2410 -9 ) and of mortality with test-confirmed COVID-19 (OR=4.29, 95% CI: 2.38 to 7.72, p=1.2210 -6 ), compared to e3e3s. For e3e4s versus e3e3s, these two associations were nominally statistically significant (at p<0.05), but with much smaller effect sizes. The e4e4 associations were similar after excluding 50,566 participants related to the 3 rd -degree or closer for test positivity (e4e4 OR=2.30, 95% CI: 1.73 to 3.07, p=1.3910 -8 ) and for mortality with test-confirmed COVID-19 (e4e4 OR=4.53, 95% CI: 2.39 to 8.61, p=3.8710 -6 ). Additionally, the e4e4 association with either COVID-19 outcome was little changed after removing participants with diseases associated with ApoE e4 alleles [5] and COVID-19 severity [6] , including dementia, hypertension, coronary artery disease (myocardial infarction or angina), or type 2 diabetes (Table 1) , based on diagnoses recorded from baseline self-reports and hospital discharge records during follow-up to March 2017. ApoE e3e4s were modestly associated with test positivity overall, and the association tended to be less marked in disease-free samples (Table 1) . In additional analyses, we tested associations with ApoE e2 alleles, which have been linked to beneficial health outcomes [5] . No associations were found between e2e3 and either of our COVID-19 outcomes (p>0.05, versus e3e3). Analyses for e2e2s associations were underpowered (n=2,427, 4 positives, and 1 positive death).

The results presented imply a recessive effect of the ApoE e4 allele. Only modest associations were present between the much more common e3e4 genotype and COVID-19 outcomes, similar to results for rs429358 (which separates 0, 1, and 2 copies of e4 alleles, OR=1.3, p=0.0026) reported for severe COVID-19 with respiratory failure in a recent additive effect genome-wide analysis [7] . ApoE e4e4 associations with test positivity and mortality were little affected by excluding dementia and other ApoE e4 associated diagnoses reported before March 2017: future work should include recent pre-existing diagnoses. More data are needed on ApoE and COVID-19 associations in other ancestry groups, as numbers of UK Biobank participants of such groups are unfortunately too small for this analysis.

In conclusion, ApoE e4e4 genotype is associated with COVID-19 test positivity at genome-wide significance (i.e., p<510 -8 ) in UK Biobank, using data covering a longer period than previously reported. M a n u s c r i p t M a n u s c r i p t 5 

APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort

Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK Biobank. figshare

Common conditions associated with hereditary haemochromatosis genetic variants: Cohort study in UK Biobank

World Health Organization. COVID-19 coding in ICD-10

ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants

PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER ADULTS IN THE UK BIOBANK COMMUNITY COHORT. medRxiv [Internet

A c c e p t e d M a n u s c r i p t 6